報價延遲最少15分鐘:2025/09/18 16:57 EDT
盤後時段
|
||||
|
14.77 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.77
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.05/0.19
|
|
企業價值
783.41M
|
| 資產負債 |
|
每股賬面淨值
6.15
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
333.79M
|
|
每股收益
5.58
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/18 16:57 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services. |
